Adaptive nonlinear model predictive control improves glycosylation control in CHO cell culture, indicating potential for enhancing mAb quality.
N-glycosylation is a critical quality attribute of monoclonal antibodies (mAbs), the dominant class of biopharmaceuticals. Controlling glycosylation remains difficult due to intrinsic pathway complexity, limited online measurements, and a lack of tailored control strategies. This work applies an adaptive nonlinear model predictive control (ANMPC) framework to a fed-batch mAb production process, using a multiscale model that links extracellular conditions to intracellular Golgi reactions to predict glycan profiles. Model parameters are updated online as new measurements arrive, after which a shrinking-horizon optimization computes the control inputs; only the first control move is implemented each cycle. Case studies show that, with a minimal day-1 galactose excitation, ANMPC mitigates model-plant mismatch and achieves up to 130% and 96% higher performance than open-loop optimization and state NMPC, respectively. Under more realistic conditions (partial measurement availability and longer preparation time), ANMPC maintains comparable performance, indicating robustness to practical limitations. Overall, the results demonstrate that ANMPC can actively shape glycan distributions in silico and offers a viable path toward closed-loop control of mAb glycosylation.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: